Objective: This study aims to prospectively assess the incidence of hypercalciuria and hypercalcemia with different doses of vitamin D and with a calcium intake of approximately 1,200 mg/day.
C alcium and vitamin D supplements are widely recommended for the prevention of osteoporosis in post menopausal women The recommended dietary allowance for vitamin D 3 and calcium in older people is 600 to 800 IU/day and 1,200 mg/day, respectively. 1 There have been many trials of the effects of vitamin D and calcium on bone; however, no systematic study of potential adverse events, such as hypercalcemia, hypercalciuria, and kidney stones, has been performed. 1 The exact dose of vitamin D associated with toxic symptoms in humans is not known, but 56 women who developed vitamin D intoxication and hypercalcemia from drinking fortified milk had serum 25-hydroxyvitamin D (25(OH)D) levels that varied from 56 to 696 ng/mL (140-1,740 mmol/L), and some women (22%) were discharged with renal impairment and metastatic calcification. 2 The tolerable upper level is 4,000 IU/day. 1 Recently, a reverse J-shaped curve demonstrated a 42% increase in mortality in 247,574 men and women with serum 25(OH)D levels higher than 55 ng/mL (137 nmol/L) compared with 20 ng/mL (50 nmol/L). 3 Studies of toxicity after high calcium intake are rare. The recommended dietary allowance for calcium in older adults aged 50 to 70 years is 1,000 to 1,200 mg/day, and the recommended upper limit is 2,000 mg/day. 1 Recent clinical cases of hypercalcemia have been attributed to increased calcium intake, usually calcium carbonate. In such cases, the total calcium intake could be as small as 1,000 to 2,000 mg/day. 4, 5 Hypercalcemia and renal failure have been reported with as little as 1,700 mg/day. 6 Another possible adverse event reported recently was a 31% increase in cardiovascular events in a metaanalysis of osteoporosis trials that used calcium supplements 7 ; however, it is not known if such can be attributed to hypercalcemia and hypercalciuria. The Women's Health Initiative (WHI) trial is the only large, long-term, prospective controlled study of calcium and vitamin D supplementation; at 7 years, it reported a 17% increase in the risk of nephrolithiasis compared with placebo in this study of 36,282 women. 8 There has never been an evidence-based evaluation of the safety of calcium and vitamin D supplements despite their widespread use. In this article, we report on the incidence of hypercalciuria and hypercalcemia measured prospectively as a secondary outcome in a clinical trial of vitamin D and calcium supplementation in older postmenopausal women.
METHODS

Study design
The clinical trial was a 1-year randomized, double-blind, placebo-controlled study (Vitamin D Supplementation in Older Women [VIDOS] ) that aimed to determine the effects of increasing vitamin D 3 doses. One hundred sixty-three white women were studied at Creighton University Medical Center (Omaha, NE). The women, aged 57 to 90 years, were at least 7 years postmenopause. The main inclusion criterion was vitamin D insufficiency, defined as a serum 25(OH)D level of 20 ng/mL (50 nmol/L) or less. Women were enrolled from winter/spring 2007 to 2008 and followed for 1 year. Complete details of the trial are given in the primary article. 9 Exclusion criteria were as follows: significant health problems, active nephrolithiasis or history of more than two kidney stones in their lifetime, chronic renal failure (serum creatinine 91.4 mg/dL), chronic liver disease, medical conditions severe enough to prevent reasonable physical activity, serum 25(OH)D levels lower than 5 ng/mL (12.5 nmol/L), serum calcium levels of 10.3 mg/dL (2.575 mmol/L) or more or serum calcium levels more than 0.3 mg/dL higher than the upper normal limit on two baseline tests, and 24-hour urine calcium levels higher than 300 mg/dL (7.5 mmol) on two baseline tests. Those currently taking bisphosphonates or who had taken them for more than 3 months in the past were excluded. Use of fluoride, parathyroid hormone (PTH) or its derivatives, calcitonin, estrogen (in the last 6 mo), corticosteroids (910 mg/d), phenytoin or phenobarbital, or high-dose thiazide (937.5 mg/d) was not allowed. Multivitamins containing vitamin D were not allowed in the study.
Randomization and treatment
Women were randomly assigned to one of eight groups: vitamin D 3 400, 800, 1,600, 2,400, 3,200, 4,000, or 4,800 IU/day, or placebo. Women, providers, researchers, and persons who assessed outcomes were blinded to treatment assignment. The statistician had access to treatment assignments. Randomized blocks with block sizes of 8 and 16, stratified by screening serum 25(OH)D levels lower than 15 versus 15 ng/mL or more (G37.4 vs Q37.4 nmol/L), were used. The study statistician generated the randomization list using SAS software (SAS Institute Inc, Cary, NC).
After analyzing dietary calcium levels from 7-day food diaries, we gave calcium citrate supplements (Citracal; Bayer HealthCare, Morristown, NJ) to women to maintain total calcium intake between 1,200 and 1,400 mg/day; they were advised to take calcium tablets twice daily and vitamin D after food intake. The Institutional Review Board at Creighton University approved the study protocol, and participants were enrolled after they have signed an informed consent form. A Data Safety and Monitoring Board was established at the beginning of the study. Adherence was measured at 3, 6, 9, and 12 months by counting the pills remaining in the bottles; new bottles of vitamin D and calcium were supplied at each of these visits.
Outcomes and follow-up
The primary outcomes of this study were dose responses to serum 25(OH)D and serum PTH after treatment with vitamin D 3 . Secondary outcomes were serum and 24-hour urine calcium.
Fasting venous blood specimens were collected at baseline and at 3, 6, 9, and 12 months. All serum and urine chemistry values were measured at the Creighton University Clinical Chemistry Laboratory using standard autoanalyzer equipment. 25(OH)D level was measured by radioimmunoassay at the Bone Metabolism Laboratory (Diasorin Inc, Stillwater, MN). The reference range for serum calcium at the Creighton University Medical Center is 8.5 to 10.2 mg/dL. Data from a previous study were used to define a reference range for 24-hour urine calcium (30-300 mg [0.75-7.5 mmol]). 10 Dietary intake of calcium and vitamin D was calculated by a dietician from the 7-day food diaries at baseline and 12 months (Food Processor II Plus nutrition and diet analysis system; ESHA Research, Salem, OR).
Management of hypercalcemia and hypercalciuria
Hypercalcemia
During the study, hypercalcemia was defined as a fasting serum calcium level that was 0.3 mg/dL or 1 SD higher than the upper reference range of 10.2 mg/dL (ie, 910.5 mg/dL). For poststudy analysis, hypercalcemia was defined as a serum calcium level exceeding the upper normal limit of 10.2 mg/dL (2.55 mmol/L).
Hypercalciuria
During the study, hypercalciuria was defined as a 24-hour urine calcium level exceeding 400 mg (10 mmol). For poststudy analysis, hypercalciuria was defined as a 24-hour urine calcium level higher than 300 mg, which is the upper normal limit. Hypercalciuria may occur spuriously when an individual collects urine specimens for longer than 24 hours. To account for this potential error of overcollection, we averaged 24-hour urine creatinine levels for all urine collections at the end of the study; if a 24-hour creatinine level was 20% higher than the mean for all tests, that episode of hypercalciuria was excluded from the analysis.
When severe hypercalciuria (9400 mg/d [10 mmol]) or hypercalcemia (Q10.5 mg/dL) developed, tests were repeated within 2 weeks. When calcium levels were elevated, calcium supplements were withdrawn, dietary calcium levels were rechecked, and laboratory tests were repeated within 2 weeks. When the elevation persisted, calcium was withdrawn. When the condition still persisted, vitamin D was withdrawn.
Statistical methods
The endpoints for this secondary analysis were urine and serum calcium. Analysis was performed using all women who were randomized. For those who dropped out or were removed from the study, the data (if available) were included in the analysis. For the purpose of this analysis, hypercalcemia was defined in the usual clinical termsVa serum calcium level of 10.3 mg/dL (2.75 mmol/L) or more. Similarly, hypercalciuria was defined as a 24-hour urine calcium level higher than 300 mg (7.5 mmol/L), and severe hypercalciuria was defined as a 24-hour urine calcium level higher than 400 mg (10 mmol/L).
Descriptive statistics are presented as means (SDs), unless otherwise specified. Mixed-effects models were used to estimate the effects of time and dose on urine and serum calcium. Dose and time were included as fixed effects in the model, and participant was included as a random effect. Log transformation was applied to urine calcium to meet modeling assumptions. Interactions between dose and time were also explored. Model fit was examined by observing various residual plots.
As post hoc comparison, we compared women with hypercalciuria by dividing them into three groups based on 24-hour urine calcium levels during the course of the study (defined as 24-hour urine)Vwomen with a urine calcium level higher than 400 mg (10 mmol), women with a urine calcium level between 300 and 400 mg (7.5-10 mmol), and women with a urine calcium level lower than 300 mg (7.5 mmol)Vin a complete case analysis (they had to have a urine calcium measurement at each time point to be included in this analysis). Analysis of variance models and W 2 tests were used to compare participant characteristics between these three categories. Variables that were significant in univariate models were used as predictors in multivariate generalized logistic regression. Estimated glomerular filtration rate was included in the model based on clinical experience.
We looked at calcium levels of 300 mg or higher at any time during the study versus calcium levels lower than 300 mg during the study, using a logistic regression model. Receiver operating characteristic (ROC) analysis was used to find a cutpoint for the variable with the greatest predictive value to give a predictive category for detecting hypercalciuria. It was also tested in a multivariate logistic model. SAS software version 9.2 (SAS Institute Inc) was used for analysis. P values less than 0.05 were considered statistically significant.
RESULTS
One hundred sixty-three women were randomized, 147 women completed the protocol, 5 women were lost to follow-up, and 11 women discontinued the study medications. Those women who discontinued the supplements came in for Table 1 . No significant differences between the eight groups were observed at baseline. The mean (SD) baseline serum 25(OH)D level was 15.6 ng/mL (39 nmol/L), which increased to 45 ng/mL (112 nmol/L) with the highest dose of vitamin D (4,800 IU/d). The mean (SD) daily dietary calcium intake was 685 (259) mg at baseline and 671 mg at 12 months. The mean calcium supplement was approximately 600 mg, and the mean total calcium intake at 12 months was 1,280 mg/day. The mean (SD) vitamin D intake was 114 (69) IU/day.
The mean (SD) overall adherence for 12 months was 94% (10%) for vitamin D 3 and 91% (18%) for calcium.
Serum calcium results
The mean (SD) baseline serum calcium level was 9.47 mg/dL (2.36 nmol/L), which increased to 9.52 mg/dL (2.38 nmol/L) at 12 months (P = 0.13). Twenty episodes of hypercalcemia (910.2 mg/dL) were observed in 14 women (Fig. 1, Table 2) . The serum calcium level peaked at 3 months and slightly declined thereafter but never reached the baseline level. There was no significant association between episodes of hypercalcemia and vitamin D dose or serum 25(OH)D level. Hypercalcemia was transient and did not lead to reduction of calcium or vitamin D doses. In retrospect, two women may have had mild primary hyperparathyroidism. They had five episodes of hypercalcemia that had been excluded from the abovementioned analysis of hypercalcemia.
24-Hour urine calcium results
The mean (SD) baseline 24-hour urine calcium level was 141 mg (3.5 mmol), which increased to 185 mg (4.6 mmol) at 12 months (P G 0.0001); changes at each time point are shown in Figure 2 . Eighty-eight episodes of hypercalciuria (9300 mg) were observed in 48 women (Fig. 3) . When we excluded overcollection of 24-hour urine based on an individual's mean 24-hour urine creatinine level, the episodes of hypercalciuria were reduced from 88 to 81, and the number of women were reduced from 48 to 47 (Table 2 ). These 81 episodes of hypercalciuria (9300 mg/d [7. 7mmol]) occurred in 32% of women. Hypercalciuria occurred once in half of women and more than once in the other half of women; supplements were reduced in five women. The two women who may have had mild primary hyperparathyroidism did not have any episodes of hypercalciuria.There was no significant association between episodes of hypercalciuria and vitamin D dose or serum 25(OH)D level. Women who developed hypercalciuria or hypercalcemia were not the same people, and only two women developed both, as shown in Figure 4 . All data were used to plot the graphs.
In 19 women, 24-hour urine calcium level increased to more than 400 mg (10 mmol); after repeated testing, urine calcium level decreased to below 300 mg (7.5 mmol) in 14 women and remained high in 5 women. Of these five women, calcium was discontinued in two women, and follow-up urine calcium level was less than 300 mg/day (7.5 mmol). However, hypercalciuria continued in two women, and both calcium and vitamin D were discontinued permanently. One woman refused follow-up testing. We found marginal associations between baseline 24-hour urine calcium and calcium intake estimated from the 7-day food diary (P G 0.074) and mean caffeine intake (P G 0.077).
Mixed-effects model
Log 10 transformation of urine calcium improved the fit of the model. Model fit was examined with various residual plots and Akaike information criterion values, and the models were determined to fit well. In fitting the model, 161 women had urine calcium at baseline, 154 women at 3 months, 148 women at 6 months, 146 women at 9 months, and 146 women at 12 months. One hundred sixty-three women had serum calcium at baseline, 154 women at 3 months, 149 women at 6 months, 148 women at 9 months, and 147 women at 12 months. Dose-time interaction was not significant for urine calcium (P = 0.20) or serum calcium models (P = 0.17). Baseline levels of 24-hour urine calcium were significantly lower than the levels at all other time points (P G 0.0001), but none of the other time points differed significantly from each other (Fig. 2) . Urine calcium levels did not change significantly with vitamin D dose. There was a significant increase in serum calcium level from baseline to 6 months (P = 0.029). However, none of the other pairwise comparisons were significant, including those between baseline and 12 months (P = 0.56). Serum calcium levels did not change significantly with vitamin D dose.
PTH results
At baseline, six women had high serum PTH levels (965 pg/mL). Serum PTH levels decreased to the reference range at 6 months in four women and remained high at 6 and 12 months in two women. In retrospect, these two women may have had primary hyperparathyroidism, and their data on serum and 24-hour urine calcium were not used. The mean PTH level decreased at the end of the study, whereas serum and 24-hour urine calcium levels increased.
Multivariate model
Generalized logistic regression was used to fit a multivariate model that predicts which women will develop hypercalciuria (300-400 and 9400 mg). We considered baseline predictors that were significant in univariate comparisons, namely, age and urine calcium level at baseline. From the model, age and urine calcium level at baseline are significant predictors of hypercalciuria. A 1-year increase in age results in a 23% decrease in 
FIG. 4.
All serum calcium and 24-hour urine calcium levels during the study. The upper reference range for serum calcium and 24-hour urine calcium is indicated by dotted lines. Only two women had both hypercalcemia and hypercalciuria; most women had either one or the other. the risk of developing 24-hour urine calcium levels higher than 400 mg (10 mmol; odds ratio [OR], 0.77; 95% CI, 0.67-0.90; P = 0.0007). The odds of having a urine calcium level of 300 to 400 mg (7.5-10 mmol) versus a urine calcium level lower than 300 mg (7.5 mmol) did not differ significantly with age (P =0.16). For every 1-mg increase in baseline 24-hour urine calcium level, there was a 3% increase in the risk of having a urine calcium level higher than 400 mg (10 mmol; OR, 1.03; 95% CI, 1.02-1.04) and a 2% increase in the risk of having a urine calcium level between 300 and 400 mg (7.5-10 mmol; OR, 1.02; 95% CI, 1.01-1.03) compared with the reference group (urine calcium G300 mg [7. 5 mmol]; P G 0.0001).
Prediction of hypercalciuria using ROC curves for urine calcium at baseline
We used ROC curves to determine a cutpoint of urine calcium at baseline that would predict a urine calcium level of 300 mg or higher during the course of the treatment. The ROC curve gave optimal sensitivity (87.2%) and specificity (70.1%), with an area under the curve of 0.85 (95% CI, 0.78-0.92) for a baseline urine calcium cutpoint higher than 132 mg (Table 3) .
We used a multivariate logistic regression model to predict a urine calcium level of 300 mg or higher during the course of the study, using the cutpoint determined for baseline urine calcium and age. A woman with a baseline urine calcium level higher than 132 mg has a 15 times greater risk of having a urine calcium level of 300 mg or higher during the course of the study than a woman with a baseline urine calcium level of 132 mg or less (OR, 15.3; 95% CI, 5.44-43.01; P G 0.0001). A 1-year increase in age results in a 10% decrease (or 0.90 times) in the risk of developing a urine calcium level of 300 mg or higher (OR, 0.90; 95% CI, 0.84-0.97; P = 0.0044).
Other cutpoints were explored for baseline urine calcium level using a multivariate logistic regression model (Table 3) . If the cutpoint was 180 mg or higher for baseline urine calcium level, there was a 20 times greater risk of having a urine calcium level of 300 mg or higher during the course of the study compared with a woman with a baseline urine calcium level lower than 180 mg (OR, 18.1; 95% CI, 6.7-49.2; P G0.0001).
Safety and adverse events
Eleven serious adverse events were observed in 11 women. Three of these adverse events were rated as severe, including diverticulitis, congestive heart failure, and tibia-fibula fracture; seven of these adverse events were described as moderate,including angina, syncope, hip surgical operation, radial fracture, chronic obstructive pulmonary disease exacerbation, stroke, and partial thyroidectomy for a nodule (none was attributed to vitamin D use). There was a small but significant increase of 0.068 mg/dL (95% CI, 0.041-0.096; P G 0.0001) in serum creatinine. One woman had an increase of 0.4 mg/dL, 4 women had an increase of 0.3 mg/dL, and 12 women had an increase of 0.2 mg/dL during 1 year. No symptomatic episodes of kidney stones were observed.
DISCUSSION
This is the first prospective controlled study to report in detail the effects of vitamin D and calcium on serum and 24-hour urine calcium levels in older women. During a year of three monthly tests, 8.8% of women developed hypercalcemia, and 32% women developed hypercalciuria.
No relationship was found between episodes of hypercalcemia or hypercalciuria and vitamin D 3 dose or serum 25(OH)D level, but 24-hour urine calcium was weakly related to the 12-month serum 25(OH)D level. Women who developed hypercalciuria seemed to be different from those who developed hypercalcemia, as shown in Figure 4 , but we found no difference in any variable to explain this finding. It is notable that hypercalcemia and hypercalciuria occurred in the placebo group that received only calcium and placebo vitamin D; thus, even a modest calcium supplementation of 600 mg/ day may be too high for some women. Sixteen percent of women increased urine calcium levels by more than 400 mg, and another 14% of women increased urine calcium levels by more than 300 mg. These results would be clinically relevant if other risk factors for stone formation are present because stone formers compose 6% of the population.
Although all of the women were vitamin DYdeficient upon entry into the study, there is no evidence that treatment with vitamin D and calcium can cause hypercalcemia and hypercalciuria in this group, as shown in a previous study. 11 Few studies have reported the occurrence of hypercalciuria or hypercalcemia. In a placebo-controlled study of 583 older women in France, participants were randomized to either calcium 1,200 mg given as calcium phosphate and vitamin D 800 IU/day or double placebo; the baseline dietary calcium level was 558 mg/day. With calcium plus vitamin D, there was a significant increase in serum calcium, but there was no information on hypercalcemia. The 24-hour urine calcium level increased from 119 to 167 mg (from 3.0 to 4.1 mmol) compared with placebo, and 3.4% of women had levels higher than 350 mg (8.7 mmol). 12 In a placebo-controlled study, 192 older women were treated twice daily with a combination tablet of vitamin D 400 IU/day and calcium 500 mg/day given as calcium carbonate; the baseline calcium intake was 736 mg. Twenty percent of women in the treatment group had 24-hour urine calcium excretion above the normal threshold compared with placebo (159 mg [4. 0 mmol] vs 94 mg [2.3 mmol]; P G 0.001).There was no significant difference in the incidence of hypercalcemia between the two groups (7.4% vs 11.5%). In a 4-year controlled study of calcium supplements given as calcium citrate only versus placebo, 236 healthy postmenopausal women with a baseline calcium intake of 711 mg/day took calcium 1,234 mg/day; thus, women had a total calcium intake of approximately 2,000 mg/day. In this study, 50% of women in the calcium-treated group and 8% in the placebo group had 24-hour urine calcium levels exceeding 350 mg/day (8.7 mmol), and 44% of women had to reduce their calcium supplement. Only one woman on calcium supplementation developed mild hypercalcemia. 14 In epidemiologic studies, the risk of stone formation increases with higher levels of urine calcium, even though stone formers are known to have other risk factors. 15, 16 In the WHI trial, 8 the group given vitamin D 400 IU/day together with a calcium supplement of 1,000 mg had a 17% increase in kidney stones compared with placebo (hazards ratio, 1.17; 95% CI, 1.02-1.34). Because the baseline dietary calcium level was 1,100 mg and the final calcium intake was 2,200 mg/ day, it was more probable that the high calcium intake was the major contributing factor given the findings in this study. It is commonly thought that vitamin D increases calcium absorption; however, we showed that vitamin D 400 IU/day had no effect on calcium absorption in this older age group of women 17 and that vitamin D up to a dose of 2,400 IU/day had no effect on calcium absorption in younger women. 18 It seems improbable therefore that vitamin D 400 IU/day could cause hypercalciuria and renal stones in the WHI trial. 8 One explanation for the absence of kidney stones in calcium intervention studies of osteoporosis is that the studies were small and lasted only 2 to 3 years compared with the WHI trial that followed women for 7 years. In the observational study from the WHI trial, there was a 2.5% incidence of kidney stones during 7 years of follow-up. Stone risk decreased by 28% with the highest quartile of dietary calcium intake and decreased by 20% with higher water intake. 19 However, the trial included women with a history of renal stones.
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In the Nurses Heath Study II of women aged 27 to 44 years, higher dietary calcium was associated with a 45% lower stone risk, but calcium supplements had no effect on stone risk. 20 Similar results were found in the Health Professional Study in men, 21 but a later analysis of the same study reported that the effects of dietary calcium on stone risk reduction only applied to men younger than 60 years and not to men older than 60 years. 22 In a 16-year follow-up of women in the Nurses Health Study I, higher dietary calcium was shown to reduce stone risk by 35%, whereas use of calcium supplements increased stone episodes by 20%; this was the first study to link calcium supplementation to stone risk. 23 The strengths of our study include the systematic measurement of serum and 24-hour urine calcium levels, use of 7-day food diaries to record nutritional intake, adjustment for known covariates, excellent compliance, and measurement of serum and 24-hour urine calcium every 3 months. We excluded women who had a baseline 24-hour urine calcium level higher than 300 mg (7.5 mmol), thereby limiting those at risk for hypercalciuria; thus, we may have underestimated the effects of the supplements.
Our study has some limitations. We did not use fixed-dose calcium; thus, women with low calcium intake received higher supplemental calcium. However, 70% of the women received an average of 600 to 800 mg/day. Because we did not have a placebo group without calcium supplementation, we could not ensure that hypercalciuria in these women was caused only by the calcium supplements.
These results may not apply to other age groups or ethnic groups because of differences in calcium and vitamin D metabolism.
Healthcare practitioners who advise women on osteoporosis prevention seldom consider the issues of hypercalcemia and hypercalciuria, which can be determined by testing serum and urine calcium levels on a continuous basis. It is known that 5% to 8% of men and women have idiopathic hypercalciuria, which is a risk factor for kidney stones; one would expect that the millions of men and women taking calcium supplements belong to this risk group. The epidemiologic studies discussed above suggest that high dietary calcium intake is associated with a lower risk for kidney stones and that calcium supplements increase the risk. 23 
CONCLUSIONS
In summary, episodes of hypercalcemia and hypercalciuria are common events with calcium and vitamin D supplementation; they are unrelated to vitamin D dose or serum 25(OH)D level. Whether they are caused by calcium alone or by the combination of calcium with vitamin D remains uncertain. Further investigation is needed to better define individuals who are likely to develop hypercalciuria and hypercalcemia, but a high baseline 24-hour urine calcium level is one predictor of hypercalciuria. Before the start of calcium and vitamin D supplementation, it is advisable to measure blood and urine calcium levels and to perform a follow-up measurement within 3 months.
